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Abstract
STAT3 is constitutively activated in a high percentage of tumours and tumour-
derived cells of both liquid and solid origin, often correlating with aggressive
disease and bad prognosis. Persistent STAT3 activity, to which tumours often
become addicted, is mostly due to the aberrant activation of pro-oncogenic/pro-
inflammatory signals that can trigger its phosphorylation, such as oncogenes,
growth factor receptors and cytokines. Among STAT3-mediated functions are
increased survival and proliferation, enhanced angiogenesis, motility and inva-
sion, and down-modulation of anti-tumour immune responses. Moreover,
STAT3 was recently shown to play unexpected roles in regulating cell metabo-
lism and mitochondrial activity via both transcriptional and non-transcriptional
mechanisms. Here, we review the main knowledge about the role of STAT3 in
solid tumours, with a particular focus on breast cancer and our recent work with
mouse models.
Introduction
Signal Transducers and Activators of Transcription (STAT) factors mediate the
signalling downstream of cytokine and growth factor receptors, and often their
activity is deregulated in cancer (Turkson and Jove 2000; Siddiquee et al. 2007).
Once activated by tyrosine-phosphorylation via receptor-associated JAK kinases,
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STATs form parallel dimers that concentrate into the nucleus regulating the
expression of target genes (Schindler et al. 2007). The family member STAT3
can be activated by a wide variety of cytokines and growth factors (e.g. IL-6
family, leptin, IL-12, IL-17, IL-10, Interferons, G-CSF, EGF, PDGF) and by a
number of oncogenes such as Src, Abl, Sis, Fps, Ros, Met and ErbB2 (Turkson
and Jove 2000). Accordingly, STAT3 is found to be constitutively tyrosine-
phosphorylated in a high percentage of tumours and tumour-derived cell lines
of both liquid and solid origin, which often become addicted to its activity for
continuous survival and growth (Yu et al. 1995; Turkson and Jove 2000;
Kortylewski et al. 2005; Siddiquee et al. 2007), and is considered a good target
for anti-cancer therapy. Indeed, STAT3 tyrosine phosphorylation and consequent
transcriptional activation was shown to be required for cell transformation
downstream of several oncogenes, the prototype being v-Src (Yu et al. 1995;
Bromberg et al. 1998; Silva 2004). Although a unique core activity determining
addiction to STAT3 by a wide spectrum of biologically distinct tumors has still
not been identified, STAT3-mediated gene expression signature is mostly con-
sistent with tumour cell survival and proliferation (Pensa 2008; Yu et al. 2009).
In addition, STAT3 constitutive activity in tumour cells can down-modulate anti-
tumour immune responses (Yu et al. 2009) as well as promote tumour angiogen-
esis (Niu et al. 2002a). STAT3 can also regulate cell movement, contributing to
cytoskeleton reorganization and controlling cell adhesion properties, and is
thought to play a role in tumour invasion and metastasis by inducing the
expression of matrix metalloproteinases (MMP) and promoting the epithelial to
mesenchymal transition (EMT) (Pensa 2008; Yu et al. 2009). Finally, recent
work has shown that STAT3 acts as an important regulator of cell metabolism,
promoting aerobic glycolysis and downregulating mitochondrial activity via its
canonical, nuclear functions (Demaria et al. 2010) while preserving mitochon-
drial respiratory activity via mitochondrial localization of its serine-
phosphorylated form (Gough et al. 2009; Wegrzyn et al. 2009). Both activities
contribute to tumor transformation downstream of distinct signals, which pro-
mote STAT3 phosphorylation on either tyrosine or serine. The pro-oncogenic
role of STAT3 was first directly demonstrated in vitro by the finding that
overexpression of the constitutively active mutant form STAT3C can transform
fibroblasts and epithelial cells (Bromberg et al. 1999; Dechow et al. 2004)
followed by in vivo experiments in transgenic or knock-in mice demonstrating
oncogenic potential in the lung, skin and breast (Li et al. 2007; Chan et al. 2008;
Barbieri et al. 2010a).
Many aspects of STAT3 biology in tumours have been extensively reviewed.
Here, we chose to summarize the main knowledge about the role of STAT3 in solid
tumours, with a particular focus on breast cancer and our recent work with mouse
models (Barbieri et al. 2010a, b; Demaria et al. 2010).
The solid tumours where STAT3 has been found to be constitutively active,
as well as its main functions and target genes are sketched in Table 1 and
detailed below.
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Epidermal Non-Melanoma Tumours
STAT3 constitutive activation was observed in several types of human epidermal
non melanoma cutaneous tumours, correlating with poor differentiation, tumour
invasion and metastasis in clinical samples of cutaneous squamous cell carcinoma
(SCC) (Suiqing et al. 2005). STAT3 involvement with metastatic potential was also
confirmed in xenograft experiments of basal cell carcinoma cells (BCC) over-
expressing IL-6, where IL-6-mediated angiogenesis supported tumour development
in part via STAT3 activation (Jee et al. 2004).
The two-stage chemical carcinogenesis model is considered a good model of
epithelial carcinogenesis, recapitulating the different phases from tumor initiation to
progression (Chan et al. 2004a). The first experimental evidence that STAT3 activa-
tion is required for epithelial tumorigenesis in vivo was obtained using this model,
where STAT3 ablation in keratinocytes completely abrogated skin tumour develop-
ment (Chan et al. 2004b). STAT3-deficient keratinocytes were more sensitive to
DMBA-induced apoptosis and STAT3 inhibition with an oligonucleotide decoy
injected into primary skin papillomas led to significant reduction of tumour volume.
STAT3was also implicated in ultraviolet B (UVB)-induced skin carcinogenesis by the
observation that UVB irradiation promoted proliferation and survival of keratinocytes
via STAT3 activation (Sano et al. 2005). Conversely, transgenic mice overexpressing
the constitutively active form STAT3C in keratinocytes developed skin tumours with
a shorter latency and in greater number compared to non-transgenic mice (Kim et al.
2007; Chan et al. 2008). STAT3C acted in both tumour initiation and promotion by
upregulating genes involved in survival, proliferation, angiogenesis and metastasis.
One key step in STAT3-mediated epithelial tumorigenesis may be the induction of
Bcl-xL, which plays a fundamental role in early skin carcinogenesis by enhancing
survival of keratinocyte stemcells in the bulge region of the hair follicle,wheremutations
are believed to arise during the initiation stage andwhose clonal expansion occurs during
tumour promotion, as shown by studies in Bcl-xL deficient mice (Kim et al. 2009).
Melanoma
STAT3 is constitutively active in the vast majority of melanoma tumours and cell
lines (Niu et al. 2002a), most often downstream of activated c-Src (Kortylewski
et al. 2005), where it favours proliferation, escape from apoptosis and angiogenesis
via induction of Bcl-xL, Mcl1 and VEGF (Niu et al. 2002a; Xie et al. 2006). STAT3
activation is apparently crucial to promote the metastatic process in melanoma,
through direct upregulation of MMP2, VEGF and bFGF expression (Xie et al. 2004,
2006). STAT3 activation was shown to promote an immunosuppressive environ-
ment leading to impaired dendritic cell (DC) maturation and tumour-specific T cell
response in melanoma B16 cells (Wang et al. 2004). Accordingly WP1066, a
STAT3 inhibitor that blocks melanoma cells growth, was found to interfere with
melanoma brain metastasis by inhibiting the production of immunosuppressive
cytokines such as TGF-b, MCP1, RANTES and VEGF by tumour cells, thus
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enhancing cytotoxic T lymphocyte responses and inhibiting T regulatory (Treg)
cells differentiation (Kong et al. 2008).
Head and Neck Cancer
STAT3 constitutive activation has been observed in 40–80% of human head and
neck squamous cell cancer (HNSCC), correlating with poor prognosis and with
proliferation and apoptosis resistance via induction of cyclin D1, Bcl2 and Bcl-xL
expression (Masuda et al. 2002b; Nagpal et al. 2002). Apoptosis could be reinstated
and tumour growth blocked by inhibiting STAT3 activity (Leong et al. 2003; Jing
et al. 2006). Therapeutic blockade of STAT3 activity also resulted in impaired
angiogenesis due to direct STAT3-mediated regulation of VEGF expression
(Masuda et al. 2007). STAT3 activation occurring upon EBV infection or
deregulated EGFR signalling in nasopharingeal cancer promotes anchorage-inde-
pendent growth and invasion (Lui et al. 2009; Wheeler et al. 2010). High STAT3
phosphorylation levels in cells from HNSCC patients are associated with the
expression of CD44 and aldehyde dehydrogenase 1 (ALDH1) stem cell markers
and with typical features of Cancer Stem Cells (CSCs) such as high tumorigenicity,
radioresistance, expression of the stemness markers Bmi, Oct4 and Nanog and of
the EMT genes Snail and Twist (Chen et al. 2008b). STAT3 inhibition in these cells
reinstated responsiveness to chemotherapy, favoured differentiation and impaired
tumorigenesis and metastasis formation (Chen et al. 2008b). Moreover, anti-tumour
immune responses were affected, with enhanced production of proinflammatory
cytokines and chemokines which, in turn, triggered DC activation and lymphocytes
migration and prompted anti-tumour immune response (Albesiano et al. 2010).
Colorectal Carcinoma
STAT3 constitutive activity was observed in colorectal carcinoma cells in about 50%
of clinical samples (Kusaba et al. 2005, 2006), correlating with proliferation and
tumour growth rate (Becker et al. 2005; Corvinus et al. 2005), and with tumour
invasion, lymph node metastasis and poor prognosis (Kusaba et al. 2005, 2006).
STAT3-related enhanced invasiveness correlates with strong expression of the
MMP1, -3, -7, and -9. MMP1 and MMP3 are direct STAT3 targets, and activated
STAT3 colocalizes with MMP1 in tumour specimens (Tsareva et al. 2007). Impor-
tantly, both NF-kB and STAT3 activation have been shown to be crucial for inflam-
mation-driven colon carcinogenesis (Greten et al. 2004; Bollrath et al. 2009;
Grivennikov et al. 2009). NF-kB activation in myeloid cells drives IL-6 expression,
whose levels are indeed increased in patients serum, and in turn IL-6 is responsible for
STAT3 constitutive activation in colon tumour cells, a paradigm that is thought to hold
true for several other inflammation-related tumours (Grivennikov and Karin 2010).
Mice lacking STAT3 in intestinal epithelial cells (IECs) showed an almost com-
plete protection from the development of the AOM/DSS model of colitis-associated
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cancer (CAC), correlating with decreased epithelial proliferation and enhanced sensi-
tivity to treatment-induced apoptosis (Bollrath et al. 2009; Grivennikov et al. 2009).
However, the role of STAT3 in colon tumorigenesis appears to be context-dependent,
as we have recently shown in ApcMin mice that this factor promotes early
tumorigenesis steps but impairs tumour progression at later stages, via regulation of
the adhesion molecule CEACAM1 (Musteanu et al. 2010).
STAT3-mediated immune suppression was shown to play an important role in
colon cancer cells (Nefedova et al. 2004; Wang et al. 2004), where tumour-derived
factors, inducing STAT3 activation in infiltrating immature myeloid cells,
prevented their differentiation into mature dendritic cells (Nefedova et al. 2004).
Other Tumours of the Gastrointestinal Tract
STAT3 constitutive activation plays a role in several other tumours that develop in
the gastrointestinal tract. In hepatocellular carcinoma (HCC) its activity is often
induced by HCV infection or IL-6 and other inflammatory cytokines and drives
tumorigenesis by promoting proliferation, survival (via Bcl-xL and cyclin D1
induction) and anchorage-independent growth (Yoshida et al. 2002; He et al.
2010). STAT3 inhibition in HCC cells impaired growth, angiogenesis and metasta-
sis while enhancing apoptosis and sensitivity to chemotherapy (Li et al. 2006;
Choudhari et al. 2007; Sun et al. 2008).
Constitutively activated STAT3 is widely observed also in pancreatic cancer,
often downstream of IL-6 or G-CSF, promoting tumour cell growth, metastasis and
angiogenesis (Wei et al. 2003) and impairing dendritic cells differentiation and
activation (Bharadwaj et al. 2007).
STAT3 phosphorylation is relatively infrequent in gastric carcinoma, but when
present it correlates with tumour cell proliferation, survival and angiogenesis via
induction of Bcl2, VEGF and survivin expression (Kanda et al. 2004; Choi et al.
2006). The analysis of human gastric cancer specimens identified correlations
between STAT3 activation and lymph node metastasis (Deng et al. 2010). More-
over, STAT3 uncontrolled activity can lead to gastric cancer, as shown by the
spontaneous development of gastric carcinomas following disruption of the integ-
rity of mucosal epithelium in gp130 knock-in mutant mice (gp130757F) that are
unable to respond to SOCS3-mediated negative feedback (Tebbutt et al. 2002).
Ovarian Cancer
Constitutive activation of STAT3 was detected in a high percentage of ovarian
cancer cell lines and human tumour specimens (94%) with respect to normal ovary
epithelium, correlating with aggressive clinical behavior and tumour progression,
and it was shown to enhance proliferation and inhibition of apoptosis through
induction of cyclin D1 and Bcl-xL expression, respectively (Huang et al. 2000;
Rosen et al. 2006). Moreover, studies in cell lines have shown that enhanced
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STAT3 activity and expression contribute to resistance to apoptosis in response to
chemotherapeutic drugs (Burke et al. 2001; Duan et al. 2006). STAT3 inhibition
leads to decreased Bcl-xL expression, sensitizing tumour cells to chemotherapy-
induced apoptosis (Burke et al. 2001). One of the main signals responsible for
STAT3 constitutive activation in ovarian cancer is its canonical activator IL-6,
which promotes angiogenesis, leading to tumour proliferation and dissemination of
malignant cells (Nilsson et al. 2005).
Prostate Cancer
Phosphorylated STAT3 was detected in the majority of human prostate cancers,
correlating with the degree of malignancy (Mora et al. 2002) and with JAK2/IL-6
signalling, which enhances proliferation and survival (Lou et al. 2000; Flowers
et al. 2005). STAT3 inhibition lead to apoptosis of tumour cell lines, both in vitro
and in vivo, through downregulation of Bcl2, cyclin D1, c-Myc, Bcl-xL and Mcl1
expression (Lou et al. 2000; Jing et al. 2004; Turkson et al. 2004; Gao et al. 2005;
Hellsten et al. 2008), and inhibited angiogenesis and tumour growth via
downregulation of both HIF1a and VEGF expression (Xu et al. 2005). The expres-
sion of the constitutively active form STAT3C in immortalized prostate epithelial
cells caused tumour transformation and enhanced cell motility by decreasing
E-cadherin level and increasing the number of lamellipodia and stress fibers
(Azare et al. 2007), suggesting a role in EMT and metastasis that was subsequently
confirmed by the observation of constitutive STAT3 activation in clinical samples
of prostate cancer metastasis, where it promoted cell motility by reorganizing the
actin and microtubule network (Abdulghani et al. 2008). IL-6 dependent STAT3
activation was shown to contribute to resistance of human prostate cancer cells to
chemotherapy (Pu et al. 2004). There appear to be correlations between STAT3
activation, tumour invasion and CSCs. In particular, invasive prostate cancer cells
were shown to display promoter methylation patterns reminiscent of those observed
in CSCs, with many differentially methylated genes belonging to the IL-6/STAT3
pathway (Mathews et al. 2010). Additionally, STAT3 was shown to interact with
the CSC marker SOX1, whose silencing decreased STAT3 activation and in vitro
invasiveness (Mathews et al. 2010). Accordingly, IL-6 was recently shown to
induce the conversion of prostate non stem cancer cells (NSCCs) into sphere-
forming CSCs, similar to what observed in breast cancer cells (Iliopoulos et al.
2011a).
Lung Carcinoma
About 50–70% of human non-small cell lung carcinomas (NSCLC) and cell lines
were shown to display constitutive STAT3 activation, correlating with enhanced
proliferation and survival (Song et al. 2003; Haura et al. 2005; van Cruijsen et al.
2009). STAT3 inhibition in these cells lead to decreased expression of a number of
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known STAT3 targets (e.g. Bcl2, Bcl-xL, Mcl1, survivin, VEGF, cyclin D1 and
c-Myc), thereby promoting apoptosis, impairing proliferation and reducing angio-
genesis (Weerasinghe et al. 2007). Interestingly, mutant EGFR forms in primary
human lung adenocarcinomas lead to STAT3 activation via IL-6 upregulation (Gao
et al. 2007). In contrast with these data, Pfeiffer and colleagues demonstrated that
STAT3 constitutive activation is characteristic of primary tumour samples from
patients with small cell lung cancer (SCLC) but not from NSCLC, and that blocking
STAT3 activation impaired anchorage-independent tumour cell growth, suggesting
the implication of STAT3 in the rapid metastasizing phenotype of SCLC (Pfeiffer
et al. 2009).
The lung was the first tissue where over-expressed constitutively active STAT3
was shown to play an autonomous pro-oncogenic role, since transgenic expression
of the STAT3C mutant form in alveolar type II epithelial cells induced lung
bronchoalveolar adenocarcinomas preceded by remarkable infiltration of inflam-
matory cells (Li et al. 2007). Tumour development correlated with enhanced
secretion of pro-inflammatory molecules and with reactivation of genes critical
for epithelial cell growth during embryonic lung development, similar to what
observed in human bronchoalveolar adenocarcinomas (Li et al. 2007). Accordingly,
STAT3 downstream genes were proposed to serve as biomarkers in human lung
adenocarcinoma and chronic obstructive pulmonary disease, which are both
induced by chronic inflammation of the lung (Qu et al. 2009).
Glioblastoma
High levels of STAT3 activation are also detected in about 95% of glioblastoma
cell lines and tumour samples, inducing proliferation and apoptosis resistance
through upregulation of Bcl-xL, Mcl1 and Bcl2 expression (Rahaman et al.
2002), and promoting angiogenesis, invasion and metastasis via upregulation of
VEGF and MMP9 expression (Loeffler et al. 2005; Liu et al. 2010). Hypoxia
resistance is a common feature of both stem cells and CSCs, which are thought to
act as tumour initiating cells (TICs) in different types of tumours, including
glioblastoma (Hemmati et al. 2003; Zhou and Zhang 2008). Resistance of these
cells to chemotherapy is often responsible for relapses and/or metastasis (Villalva
et al. 2010). The highly hypoxic glioblastoma microenvironment triggers STAT3-
mediated induction of VEGF, HIF1, MMP2 and Twist1, which in turn promote
angiogenesis and tumour invasion (Kang et al. 2010). Interestingly, STAT3 activa-
tion was shown to be essential for glioblastoma stem cells proliferation and ability
to form neurospheres, and inhibition of its activity triggered the downregulation of
genes associated with the stem cell phenotype (Sherry et al. 2009) and sensitization
to chemotherapeutic treatment, suggesting that combined chemotherapy and
STAT3 inhibition may allow more efficient killing of CSCs. STAT3 activation in
glioblastoma is often supported by the constitutive expression of IL-6 in tumour
cells, and indeed IL6!/! mice were protected from glioblastoma development
(Brantley and Benveniste 2008). Abnormal activation of the FGFR and EGFR
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pathways also correlated with STAT3 phosphorylation (Brantley and Benveniste
2008). Interestingly, however, while STAT3 could cooperate with the oncogenic
mutant form EGFRvIII to mediate cell transformation, it accelerated disease pro-
gression in glioblastomas induced by PTEN-loss. Thus, depending on the genetic
background, STAT3 activity in glioblastoma can be either tumour-suppressive or
tumour-promoting (de la Iglesia et al. 2008).
Other Solid Tumours
A low percentage of rhabdomyosarcomas showed STAT3 activation that is linked
to enhanced proliferation and resistance to apoptosis (Chen et al. 2007b) and
correlating with the overexpression of the stem cell marker Piwil2, recently found
associated to different tumours. Piwil2 can activate STAT3, which in turn enhances
tumour cell survival through Bcl-xL induction (Lee et al. 2006). Moreover, STAT3
can interact with PAX3-FKHR, an oncogenic fusion protein specifically associated
with an aggressive rhabdomyosarcoma metastatic subtype. This association leads to
a reduction in tumour MHC expression and to an altered cytokine microenviron-
ment that inhibits inflammatory cells action and hampers immune detection of
tumour (Nabarro et al. 2005).
STAT3 activation was observed in 100% of renal carcinomas, correlating with
poor prognosis and metastatic disease and promoting proliferation and survival
(Horiguchi et al. 2002a, b). Pharmacological inhibition of STAT3 not only favoured
the apoptotic action of chemotherapeutic agents on tumour cells, but also
downmodulated their angiogenic and metastatic potential while improving
antitumour immune response by reducing myeloid suppressor and Tregs cells
(Xin et al. 2009).
About 60% of cervical cancers display STAT3 phosphorylation, correlating with
poor prognosis (Takemoto et al. 2009) and linked to increased proliferation and
apoptosis resistance via induced expression of Bcl2, survivin, Mcl1 (Chen et al.
2007a) and enhanced angiogenesis mediated by VEGF (Wei et al. 2003).
Finally STAT3 activation in bladder cancer cells, although limited, was
implicated in tumour cells proliferation and invasion (Itoh et al. 2006; Chen et al.
2008a).
Breast Cancer
Persistently phosphorylated STAT3 is detected in 30–60% of primary breast
carcinomas (Garcia et al. 2001) correlating with poor response to therapy (Diaz
et al. 2006) and with regional lymph node metastasis (Hsieh et al. 2005), although a
correlation with a good prognosis of node-negative cancers was suggested (Dolled-
Filhart et al. 2003). High STAT3 phosphorylation levels are detected in several
human breast cancer cell lines, where its inactivation leads to growth arrest and cell
death (Garcia et al. 1997, 2001). Similar to most other solid tumours, STAT3
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activity in breast cancer has been linked to enhanced proliferation and survival, to
resistance to apoptosis and to cell movement, invasion and metastasis.
Pathways Leading to Persistent STAT3 Activation in Breast
Cancer
Despite the wide range of tumours where STAT3 is constitutively active, so far no
activating genetic mutations have been described, suggesting that abnormal STAT3
activity in neoplastic cells must be triggered by deregulated upstream signalling. In
breast cancer, STAT3 activation shows positive correlation with EGF and ErbB2
receptors overexpression and with Src activation (Berclaz et al. 2001; Diaz et al.
2006; Leslie et al. 2006), all of which have been shown to lead to STAT3
phosphorylation, albeit not directly (Berishaj et al. 2007). V-Src was the first
oncogene whose transforming activities were shown to require STAT3 (Bromberg
et al. 1998). Additionally, STAT3 was reported to be a substrate of the breast
tumour kinase (Brk), distantly related to the Src family (Liu et al. 2006).
An impressive body of data points towards IL-6 as the main trigger for STAT3
aberrant activation in solid tumours, which at hindsight is perhaps not surprising
since IL-6 and its family of related cytokines are among the most prominent
inducers of STAT3 activity. In breast cancer patients, serum IL-6 levels are
elevated (Jiang et al. 2000; Kozłowski et al. 2003), and correlate with advanced
tumour stage (Kozłowski et al. 2003), increased number of metastatic sites
(Salgado et al. 2003) and overall poor prognosis (Zhang and Adachi 1999)
(Bachelot et al. 2003; Salgado et al. 2003). High local IL-6 production is also
detected, correlating with tumour grade (Chavey et al. 2007). Indeed, inflammation-
induced IL-6 produced either systemically or locally by tumour infiltrating inflam-
matory cells is believed to start a positive loop by activating STAT3 in cancer cells
(Grivennikov and Karin 2010). This in turn induces the secretion of soluble factors
promoting STAT3 activation and anergy in the antigen presenting cells, finally
leading to enhanced tumour cell survival and growth both via cell autonomous and
immune-mediated mechanisms (Yu et al. 2009). An oncogene-driven inflammatory
loop was also implicated in the initial stages of tumour transformation. Indeed,
transient Src activation generates an inflammatory signal which triggers an epige-
netic switch to cancer cells via a positive feedback loop involving NF-kB, Lin28,
let-7 and IL-6 (Iliopoulos et al. 2009). IL-6-activated STAT3 is essential for this
switch via direct induction of miR-21 and miR-181b-1, which target the PTEN and
CYLD tumour suppressor genes, respectively. Their downregulation in turn leads to
NF-kB activation, required to maintain the transformed state (Iliopoulos et al.
2010). The importance of this circuit was first demonstrated in transformation of
mammary epithelial cells and subsequently confirmed in prostate, colon, lung and
hepatocellular carcinoma cells.
IL-6-induced STAT3 activation is normally transient, due to tight negative
feedback control such as that mediated by SOCS3 (Yoshimura 2005). What are
the mechanisms helping to maintain persistent STAT3 phosphorylation in tumours?
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Loss of negative feedback via silencing of SOCS factors has been shown to occur in
several systems (Baltayiannis et al. 2008). Recently, it was shown that the low but
constitutive activation of STAT3 in different tumours, including the breast, is at
least partly mediated by the elevated expression of S1PR1, the receptor for the
lysophospholipid sphingosine-1-phospate. S1PR1 is a STAT3 transcriptional target
which in turn upregulates IL-6 expression and enhances STAT3 activation,
establishing a positive feedback loop resulting in STAT3 persistent activation in
both the tumour cells and the tumour microenvironment, accelerated tumour
growth and malignant progression (Lee et al. 2010).
Other cytokines belonging to the IL-6 family, such as LIF (Quaglino et al. 2007)
and leptin (Park et al. 2010), are also elevated in breast tumours, driving STAT3
activation. In particular, adipocyte-derived leptin is present at high concentrations
within the mammary gland of obese individuals, is considered as a risk factor in
several types of cancers and is proposed to correlate with breast cancer progression
(Garofalo et al. 2004). Estrogen receptor alpha was shown to enhance leptin-
mediated STAT3 activation (Binai et al. 2010), and inactivation of the peripheral
leptin receptor attenuates tumour progression and metastasis in an MMTV-PyMT
model of breast cancer, via inactivation of the ERK1/2 and Jak2/STAT3 pathways
(Park et al. 2010).
STAT3-Mediated Features: Proliferation and Survival
Most cell lines displaying persistent STAT3 phosphorylation are addicted to its
activity for proliferation and survival, both in vitro and in vivo (Garcia et al. 2001;
Hsieh et al. 2005; Diaz et al. 2006), at least partly correlating with the induction of
the anti-apoptotic genes survivin/BIRC5 and Bcl-xL and of cyclin D1 (Siddiquee
et al. 2007). Indeed, high levels of activated STAT3 correlate positively with
elevated cyclin D1 mRNA and protein expression in breast tumours and cell lines
(Leslie et al. 2006) and STAT3 can directly bind to the promoter of the human
cyclin D1 gene (Leslie et al. 2006; Saxena et al. 2007). Moreover, cyclin D1
appears to be required for mouse fibroblasts anchorage-independent growth down-
stream of constitutively active STAT3C or v-Src (Leslie et al. 2006). Interestingly,
the progesteron receptor was shown to act as STAT3 coactivator by inducing ErbB2
nuclear translocation and the assembly of a transcriptional complex on the cyclin
D1 promoter (Be´guelin et al. 2010).
Immunohistochemical analyses of invasive breast carcinomas also showed a
positive correlation between activated Src, phosphorylated STAT3 and the expres-
sion of survivin, a member of the inhibitor of apoptosis protein family (Diaz et al.
2006). Like cyclin D1, also survivin is a direct STAT3 transcriptional target, and
STAT3 silencing leads to survivin downregulation and apoptotic death in a human
breast cancer cell line (Gritsko et al. 2006). In addition to downregulating survivin
and Bcl-xL expression, STAT3 silencing in human breast cancer cells was recently
shown to lead to Fas-mediated intrinsic apoptotic pathway via the activation of
caspases-8, -9, -3 and PARP1 cleavage (Kunigal et al. 2009).
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The pro-survival role of STAT3 might be exploited for therapeutic purposes in
combined treatments. For example, the inhibition of STAT3 in metastatic breast
cancer cells enhanced the proapoptotic effects of doxorubicin, at least in part
interfering with survivin and Bcl-xL expression (Gariboldi et al. 2007). Recently,
ErbB2-activated STAT3 was shown to directly upregulate the p21(Cip1) gene in
breast cancer cells, resulting in increased Taxol resistance and suggesting that Src
and STAT3 inhibitors may be used in Taxol sensitization of ErbB2-overexpressing
breast cancers (Hawthorne et al. 2009).
STAT3-Mediated Features: Migration, Invasion and Metastasis
Activated STAT3 levels have been reported to correlate with invasiveness and
metastasis in breast cancer (Hsieh et al. 2005), and indeed a leading role for STAT3
in driving migration, invasion and metastatic disease of breast cancer cells has
emerged in the past years, and thoroughly explored in mouse models of ErbB2-
driven tumorigenesis genetically modified for STAT3 (see next section). Both
transcriptional and non-transcriptional mechanisms have been proposed to drive
STAT3-induced migration.
Intriguingly, activated STAT3 was shown for the first time in ovarian cancer
cells to localize not only to the nucleus but also to the focal adhesions, interacting
with activated paxillin and focal adhesion kinase, implying local regulation of focal
adhesions and integrin-mediated cell movement (Silver et al. 2004). We also have
observed STAT3 localization to focal adhesions in mouse breast cancer cell lines
derived from MMTV-Her2 transgenic tumours, which was enhanced in cells
derived from mice expressing constitutively active STAT3C and displaying more
aggressive and invasive tumour phenotype (Barbieri et al. 2010a). Cytoplasmic,
non-phosphorylated STAT3 was reported to induce cell migration by interacting
with, and inhibiting, the microtubules destabilizer stathmin, thus enhancing
microtubules polymerization in murine embryonic fibroblasts (Ng et al. 2006).
Conversely, several microtubule-based drugs were shown to modulate STAT3
activity by reducing its phosphorylation in breast tumour cell lines, possibly
explaining part of their therapeutic mechanism (Walker et al. 2010).
STAT3-mediated invasion has been linked to the ability to directly upregulate
the transcription of MMP9, whose expression levels correlated with those of
phosphorylated STAT3 in primary breast cancers. MMP9 was required for mam-
mary epithelial cells transformation mediated by constitutively active STAT3
(Dechow et al. 2004), and its downregulation by the trimeric resveratrol derivative
LYR71 correlates with suppression of STAT3 activation, tumour migration and
invasion in mouse breast cancer cells (Kim et al. 2008). Additionally, upregulation
of the Fra-1 oncogene in response to tumour associated macrophages lead to a
malignant switch in breast tumour cells, via activation of the IL-6/JAK/STAT3 loop
and increased release of MMP9, VEGF and TGF-b (Luo et al. 2010). Interestingly,
STAT3 apparently regulates different subsets of MMPs in different kinds of cancer
318 L. Avalle et al.
including MMP2 in melanoma (Xie et al. 2004), MMP1 in the bladder (Itoh et al.
2006) and MMP1, -3, -7, and -9 in the colon (Tsareva et al. 2007).
STAT3-driven metastasis formation was also linked to its ability to induce
anchorage-independent growth, EMT and angiogenesis. Impaired in vivo metasta-
sis due to reduced angiogenesis was reported to occur as a consequence of
inhibiting STAT3 activation by expressing a dominant negative form of gp130 in
a human breast cancer cell line (Selander et al. 2004), correlating with increased
expression of the tissue inhibitor of metallo-proteinase 3 (TIMP-3). On the other
hand, VEGF is a direct STAT3 transcriptional target, and its upregulated produc-
tion by STAT3 is believed to induce angiogenesis in different cancer types includ-
ing the breast (Niu et al. 2002b).
Metastatic breast cancer cells display increased expression of the EMT tran-
scription factor Twist1, which is required for EMT and breast cancer metastasis. A
strong positive correlation between active STAT3 and Twist1 levels was detected
in late stage breast cancer tissues and in subpopulations of human breast cancer cell
lines displaying enhanced invasiveness (Lo et al. 2007; Cheng et al. 2008c). In these
cells, STAT3 inhibition lead to Twist1 downregulation correlating with impaired
migration, invasion and colony formation, all of which could be rescued by Twist1
re-expression. Interestingly, it was recently shown that IL-6, the canonical STAT3
activator, induces EMT in the ERa-positive human breast cancer cell line MCF-7,
including impaired E-cadherin expression and induction of vimentin, N-cadherin,
Snail and Twist1. Conversely, constitutive expression of Twist1 triggered aberrant
IL-6 production and STAT3 activation, suggesting a positive loop promoting
autocrine IL-6 production (Sullivan et al. 2009). Finally, STAT3 was required for
EGF-induced Twist1 upregulation in human breast carcinoma cells by directly
binding to its promoter (Lo et al. 2007). Correlations between STAT3 and Twist1
were observed also in mouse cells. The silencing of STAT3 in the metastatic mouse
breast cancer 4T1 cell line is sufficient to impair tumour formation in vivo and
invasion ability in vitro, correlating with reduction of c-Myc, activated Src and
Twist1 (Ling and Arlinghaus 2005). However, no putative STAT3 binding site was
detected in the murine Twist1 promoter, suggesting different modes of STAT3-
dependent activation in the human and the mouse (Lo et al. 2007).
Finally, IL-6 paracrine/autocrine production and STAT3 activation were
recently shown to take part in the cross-talk between cancer cells and tumour
microenvironment to regulate motility, aggressiveness, angiogenesis and metasta-
sis. Mesenchymal stem cells (MSCs), which reside in the bone marrow, are likely to
come in contact with extravasated, metastasis-initiating breast cancer cells. These
cells were shown to enhance tumour aggressivity and growth rates in ER-alpha-
negative breast cancer cell lines via IL-6 secretion and STAT3 activation (Sasser
et al. 2007). MSCs have also been shown to selectively migrate to hypoxic breast
tumours, where they are thought to play a tumour-promoting role. Tumour-pro-
duced IL-6 acts as an attractant for MSCs, leading to their cytoskeletal reorganiza-
tion via STAT3 activation (Rattigan et al. 2010). Once within strict contact, a
positive loop is likely to get started, whereby infiltrating MSCs in turn produce IL-6
and enhance STAT3 activation in the cancer cells. Due to their specific ability to
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migrate to and engraft into primary breast tumours, genetically modified
MSCs over-expressing Interferon-b (IFN-b) have been explored as potential thera-
peutic means. IFN-b producing MSCs suppressed breast cancer cells growth
and pulmonary and hepatic metastases mainly via inhibition of STAT3 signalling
(Ling et al. 2010).
Growth and spread of cancer is thought to be mainly driven by a small subpopu-
lation of CSCs, the only cells capable of long-term self renewal and of generating
phenotypically diverse tumour cell populations. These slowly-replicating, self-
maintaining cells are resistant to most chemotherapeutics, thus driving relapse.
STAT3 is prominently involved in maintaining the undifferentiated status of mouse
embryonic stem cells (Burdon et al. 2002), and was shown to be critical for the
viability and maintenance of the stem-like side population in the MCF-7 breast
cancer cell line (Zhou et al. 2007). Additionally, experimental evidence implied
IL-6 signalling in driving formation and malignancy of breast cancer stem cells.
Sansone and co-authors reported that mammospheres from node invasive basal-like
breast carcinoma tissues, an aggressive breast carcinoma variant showing stem
cell features, produce high levels of IL-6, and that autocrine IL-6 signalling
sustain the aggressive features of hypoxia-selected MCF-7 cells (Sansone et al.
2007). Recently, IL-6 was shown to drive the conversion of nonstem cancer cells
in CSCs in human breast tumours and cell lines (Iliopoulos et al. 2011a). The
intimate relationship of STAT3 with the IL-6 pathway leads to postulate its
involvement in these systems, even though its activation was not specifically
explored.
Role of STAT3 in ErbB2-Driven Mammary Tumorigenesis: Lessons
from Mouse Models
Overexpression of the rat oncogenic form of the human EGF receptor ErbB2 (Neu)
in the mammary gland under the MMTV promoter triggers the onset of invasive
multifocal breast carcinomas at high multiplicity and is widely used as a model for
human breast cancer (Guy et al. 1996). The role of STAT3 in Neu-mediated
tumorigenesis has been studied by several groups including ours, suggesting a
pivotal role of STAT3 in driving tumour progression and metastasis that is in
agreement with the clinical and experimental observations reported above. All
studies suggest that, although not required for Neu-driven breast tumours onset
and growth, STAT3 is heavily implicated in the formation of lung metastasis by a
variety of mechanisms. Analyzing the role of b4 integrin in ErbB2 signalling by
deleting the b4 signalling domain in the context of MMTV-Neu transgenic mice,
Guo and colleagues have shown that b4 integrin forms a complex with ErbB2,
enhancing the activation of the transcription factors STAT3 and c-Jun. While
c-Jun is required for hyperproliferation, STAT3 contributes to disruption of
epithelial adhesion and polarity, and is required for cell invasion and experimen-
tal metastasis (Guo et al. 2006). In agreement with this finding, Cre-mediated
STAT3 loss of function in MMTV-Neu transgenic mice has shown that STAT3 is
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not required for the onset and growth of breast tumours, but its deletion results in
a dramatic reduction of lung metastasis by both primary and xenografted tumours
(Ranger et al. 2009; Barbieri et al. 2010b). The reduced malignancy of STAT3-
deficient tumours was partly due to an inhibition of both inflammatory and
angiogenic responses, normally activated in a STAT3-dependent transcriptional
cascade involving C/EBPd (Ranger et al. 2009). Additionally, STAT3 is required
in a cell autonomous fashion to warrant anchorage-independent growth and the
ability to produce lung metastasis in immuno-depressed mice (Barbieri et al.
2010b).
In an effort to reproduce the relatively low but persistent activation of STAT3
observed in most tumours, we have generated knock-in mice expressing at physio-
logical levels the constitutively active mutant form STAT3C. In agreement with the
results obtained with the loss of function mutants, MMTV-Neu transgenic mice
carrying the STAT3C allele developed earlier onset, more aggressive tumours with
lower levels of spontaneous apoptosis but similar proliferation rates (Barbieri
et al. 2010a). Tumour-derived STAT3C/Neu cell lines displayed enhanced
migration and invasion in vitro and increased tumorigenic and metastatic poten-
tial in vivo, correlating with a profoundly modified organization of cell-cell
contacts showing altered, irregular distribution of both adherent and tight
junctions components such as E-cadherin, b-catenin and Zo-1. Cytoskeletal
organization was also perturbed, with actin redistributing from a cortical locali-
zation typical of well differentiated epithelial cells to form abundant actin stress
fibres, typical of highly migratory cells (Pellegrin and Mellor 2007). Several
genes consistently expressed at higher levels in all three STAT3C/Neu cell lines
are known players in regulating cell migration and/or tumour metastasis, includ-
ing the STAT3 transcriptional target Twist1, involved in tumour invasiveness and
EMT (Lo et al. 2007; Cheng et al. 2008c).
In addition, we identified the atypical tensin family member Cten as a novel
STAT3 target. Cten was recently shown to mediate EGF-induced migration (Katz
et al. 2007), to promote colon cancer tumorigenicity and cell motility (Albasri et al.
2009; Liao et al. 2009), and to correlate positively with tumour stage in thymomas,
lung tumours and gastric tumours (Sasaki et al. 2003a, b; Sakashita et al. 2008), all
displaying constitutive STAT3 activity. It is the most consistently upregulated gene
in both STAT3C-expressing cell lines and tumours, and is involved in both their
increased migration and disruption of cell junctions organization (Fig. 1, adapted
from Barbieri et al. [2010a]). Moreover, we could show that Cten is induced by IL-6
in MCF10 mammary epithelial cells. IL-6-mediated induction is STAT3-depen-
dent, suggesting that indeed Cten may represent an important functional mediator
in the inflammation-STAT3-migration-metastasis loop. Indeed, CTEN expression
is particularly elevated in the extremely aggressive and invasive inflammatory
breast cancers, correlating with high EGFR and HER2 levels, loss of oestrogen
receptor, high tumour grade and node metastasis (Katz et al. 2007). Thus, CTEN
may represent an important point of functional convergence between inflammation-
driven STAT3 activity, altered EGFR/ErbB2-mediated signalling and invasion of
the surrounding tissues.
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Concluding Remarks
STAT3 has come a long way since its discovery in the 90s as STAT1’s little
brother. Initially thought to be almost an IL-6-family-dedicated factor, it has soon
emerged as one of the most pleiotropic STATs from many points of view, all
contributing to its widespread role in tumours. First, its ever-growing number of
upstream activating pathways including many that are aberrantly active in tumours,
as initially hinted by the lethal phenotype of STAT3 null embryos. Second, the
tissue-dependent variety of target genes, reflected in its variegated functions. Third,
its novel non-canonical roles, which apparently do not involve its transcriptional
activities. Importantly, its improperly prolonged activity is pro-oncogenic both in
Fig. 1 Both Stat3 inhibition and Cten silencing partially revert the aggressive phenotype of Stat3C
expressing cells. Adapted fromREF. STAT3C/Neu cells were either treated with the S3I inhibitor for
the indicated lengths of time (a, b) or transfected with an siRNA against Cten (c–e). S3I treatment
downregulates STAT3 phosphorylation (p-Stat3) and Cten expression, as shown byWestern blot (a).
Both treatments significantly impaired FCS-stimulated Transwell migration (b, d). Values are shown
as mean numbers " SEM of migrated cells per microscopic field (20#) of triplicates in one
representative experiment out of two independently performed (p < 0.05). (e) phase contrast and
immunofluorescence images of Cten-silenced cells. Arrows indicate evident discontinuous (si-ctrl)
versus tight (si-Cten) cell-cell contacts. Blue, nuclei; green, b-catenin; red, Zo-1. The insects (4#
magnification) correspond to the areas indicated by an asterisk. Scale bar, 20 mm
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tumour and stromal cells, and indeed STAT3 is emerging as a key factor in
mediating the cross talk between microenvironment and tumour cells and a main
player in inflammation-driven tumorigenesis. Despite the intense research for
STAT3 inhibitors, transcription factors are certainly not easily druggable targets.
The understanding of STAT3 biology therefore, including which upstream events
drive its activation and which are its main effectors in specific tumours, is still
highly relevant on the agenda.
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